Performing elective cardiac invasive procedures during the COVID-19 outbreak: a position statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

Abstract

The rearrangement of healthcare services required to face the coronavirus disease 2019 (COVID-19) pandemic led to a drastic reduction in elective cardiac invasive procedures. We are already facing a "second wave" of infections and we might be dealing during the next months with a "third wave" and subsequently new waves. Therefore, during the different waves of the COVID-19 pandemic we have to face the problems of how to perform elective cardiac invasive procedures in non-COVID patients and which patients/ procedures should be prioritised. In this context, the interplay between the pandemic stage, the availability of healthcare resources and the priority of specific cardiac disorders is crucial. Clear pathways for "hot" or presumed "hot" patients and "cold" patients are mandatory in each hospital. Depending on the local testing capacity and intensity of transmission in the area, healthcare facilities may test patients for SARS-CoV-2 infection before the interventional procedure, regardless of risk assessment for COVID-19. Pre-hospital testing should always be conducted in the presence of symptoms suggestive of SARS-CoV-2 infection. In cases of confirmed or suspected COVID-19 positive patients, full personal protective equipment using FFP 2/N95 masks, eye protection, gowning and gloves is indicated during cardiac interventions for healthcare workers. When patients have tested negative for COVID-19, medical masks may be sufficient. Indeed, individual patients should themselves wear medical masks during cardiac interventions and outpatient visits. KEYWORDS • miscellaneous • stable angina • COVID-19 ACS acute coronary syndrome AGPs aerosol generating procedures COVID-19 coronavirus disease 2019 ED emergency department HCWs healthcare workers NSTEMI non-ST-elevation myocardial infarction PPCI primary percutaneous coronary intervention PPE personal protective equipment STEMI ST-elevation myocardial infarction

Transcatheter aortic valve implantation for degenerated aortic valves: Experience with a new supra‐annular device. The Spanish Allegra valve‐in‐valve (SAVIV) registry

“…During the study period, 29 patients with degenerated aortic valve bioprosthesis were treated with TAVI in Spain (Figure 1). Despite COVID‐19 pandemic, that tremendously impacted on the activity of the catheterization laboratories during 2020, 13,14 ≈50% of patients were included in this year.…”

COVID-19, the Pandemic of the Century and Its Impact on Cardiovascular Diseases

“…Overall, cardiovascular procedures for patients with acute disease were preserved, whereas those for patients with stable disease were postponed. [ 27 ]…”

MitraClip for mitral valve regurgitation and transcatheter aortic valve implantation for severe aortic valve stenosis: state-of-the-art

“…Many hospitals decided to limit TAVI and MitraClip procedures to urgent cases or highly symptomatic patients [61]. Recently, a few position papers postulated recommendations for percutaneous treatment of structural heart diseases during the COVID-19 pandemic [61][62][63][64]. Limited anesthetic and intensive care facilities raise the need for triage of patients and performing procedures only in selected cases with minimal resources.…”

“…With pandemic abatement, healthcare systems might face substantial waiting lists and a high burden of patients with progression of symptoms. Significant delay in treatment might be associated with detrimental outcomes even in populations initially considered as low risk [61][62][63][64].…”